

Dr. Jeffrey Ellenbogen
Direct Testimony & Schedule

State of Minnesota
Court of Administrative Hearings
For the Public Utilities Commission

In the Matter of the Application for a Certificate of Need for the PowerOn Midwest 765 kV and
345 kV High Voltage Transmission Line Project

MPUC Docket No. E002, ET2, ET6675/CN-25-117

CAH Docket No.: 28-2500-41617

Direct Testimony of Dr. Jeffrey Ellenbogen

August 13, 2026

TABLE OF CONTENTS

I.	INTRODUCTION AND QUALIFICATIONS	1
II.	TESTIMONY OVERVIEW	4
III.	NOISE.....	5
IV.	MAGNETIC FIELDS.....	7
V.	CONCLUSION.....	11

I. INTRODUCTION AND QUALIFICATIONS

Q. Please state your name and business address.

A. My name is Dr. Jeffrey Ellenbogen. My businesses are located in Baltimore, Maryland.

Q. By whom are you employed and in what capacity?

A. I am the President of Ellenbogen Scientific, LLC; the Medical Director of tele Neurology Clinics and Director of The Sound Sleep Project.

Q. Please briefly describe your educational background and professional experience.

A. I received a Bachelor of Arts from the University of Michigan, a Master of Medical Sciences degree from Harvard Medical School, and a Medical Doctor degree from Tufts University. After medical school, I went to the University of Pennsylvania where I completed an internship in internal medicine, residency in neurology, and fellowship in clinical electrophysiology. I then completed a two-year postdoctoral fellowship in Sleep, Circadian, and Respiratory Neurobiology at Harvard Medical School.

After completing my education, listed above, I joined the faculty at Harvard Medical School as an assistant professor of Neurology where I taught “The Neurobiology of Sleep” and conducted research in brain sciences of sleep, including noise-induced sleep disruption. At the same time, I was Director of the Division of Sleep Medicine, and was Staff Neurologist, both at the Massachusetts General Hospital (MGH), located in Boston, Massachusetts.

I then joined faculty as Assistant Professor at Johns Hopkins University, in Baltimore, Maryland, where I continued my research on noise and health, and I saw patients with sleep disorders or neurological conditions. I then joined the US Department of Defense as Vice Chair of Neurology at the Uniformed Services University (USU) and as medical doctor at Walter Reed National Military Medical Center (WRNMMC). My academic appointments at USU were Associate Professor of Neurology and of Military and Emergency Medicine. In 2019 and 2020, I deployed overseas as part of Operation Freedom’s Sentinel.

1 I am currently President of Ellenbogen Scientific, LLC. In this capacity, my focuses
2 include sleep and brain health, in scientific, consulting and clinical care. Specifically, I am
3 Medical Director of tele Neurology Clinics, where I provide medical care for patients with
4 either sleep disorders, neurological conditions, or both; and I am Director of The Sound
5 Sleep Project, where I continue my research, writing and scientific-related consulting at
6 the interface of noise and human health. A comprehensive list of my training, experience,
7 publications and education is included in my curriculum vitae (CV), which is attached as
8 **Schedule 1** to this testimony.

9
10 **Q. Please describe your clinical experience as a physician.**

11 A. I am a licensed and practicing physician and have been for more than 20 years. My clinical
12 work experience includes practice as a neurologist and sleep-medicine specialist at the
13 following hospitals: MGH, Johns Hopkins Hospital, and WRNMMC. At WRNMMC, I
14 also worked within the Otolaryngology Department (*i.e.*, ENT: ear, nose, and throat) caring
15 for patients with hearing, vertigo, and balance problems; and at National Intrepid Center
16 of Excellence (NICoE) caring for active-duty military with traumatic brain injury from
17 combat, and the associated neurological or sleep-medicine problems. My current clinical
18 work is in telemedicine as a neurologist and sleep-medicine specialist for tele Neurology
19 Clinics.

20
21 **Q. Do you have experience with acoustics?**

22 A. Yes. First, the hearing mechanics are part of the nervous system, and disorders of hearing
23 are included in neurology training and practice. I've specifically worked clinically with
24 hearing programs, including in my work for the U.S. Department of Defense. My research
25 program includes the interface of noise and sleep and health, for which I have published
26 research. And I consulted for several years with Bose Corporation, working with acoustical
27 engineers on consumer-based technology for sound and human health.

28
29 **Q. Do you have any formal training or experience in electromagnetism?**

30 A. Yes. I completed a fellowship in clinical electrophysiology at the University of
31 Pennsylvania. The focus of this included applied concepts in electromagnetism, with

1 respect to human health. As a neurologist and sleep-medicine specialist, I routinely
2 examine electromagnetic aspects of human physiology and health.

3
4 **Q. In addition to neurology and sleep medicine, do you have specific experience with**
5 **cancer?**

6 A. Yes. I worked in two pediatric cancer research laboratories at Harvard Medical School.
7 The first was under Dr. Judah Folkman of Boston Children's Hospital examining novel
8 pathways for cancer development and treatment. The second was under Dr. Jane Weeks of
9 the Dana-Farber Cancer Institute examining cases of cancer in children, principally
10 pediatric leukemia. These were over a four-year period.

11
12 **Q. Did your work with cancer lead to peer-reviewed scientific publications that you co-**
13 **authored?**

14 A. Yes. I published a paper on a model of cancer that examined circulating blood factors as a
15 model for the diagnosis and treatment of cancer. This was published in the Journal of
16 Pediatric Surgery.¹ And I co-authored a paper on the clinical factors impacting terminal
17 cancer in children, most of them leukemia, published in the New England Journal of
18 Medicine.²

19
20 **Q. Do you have any teaching experience?**

21 A. Yes. For several years I taught several courses, including a year-long neurobiology course
22 at Harvard, entitled "The Sleeping Brain." In this course we examined the science of sleep.
23 I received the Certificate of Distinction in Teaching from the students; and from the faculty
24 I received the John Dowling Teaching Award in Neurobiology. I also taught numerous
25 courses for the U.S. Department of Defense, including lectures in the classroom and field.

¹ Soutter AD, Ellenbogen J, Folkman J. Splenosis is regulated by a circulating factor. *Journal of Pediatric Surgery*. 1994;29:1076-9.

² Wolfe J, Grier HE, Klar N, Levin SB, Ellenbogen JM, Salem-Schatz S, Emanuel EJ, Weeks JC. Symptoms and suffering at the end of life in children with cancer. *New England Journal of Medicine*. 2000;342:326-33.

1 These focused primarily on aspects of neurologic care and sleep medicine that might be
2 encountered in combat operations.

3 **Q. Has your work led to national awards?**

4 A. Yes. I received the Wayne Henning Sleep Investigator Award from the American Academy
5 of Neurology.
6

7 **Q. What kinds of subject matter were covered in your master's degree program, and
8 what was its purpose?**

9 A. I completed a master's degree in medical science at Harvard Medical School. The purpose
10 was to provide medical doctors with formal education to critically assess and conduct
11 research in human health. Coursework included subjects of bio-statistics, research
12 methods, health technology, and public health.
13

14 **Q. For whom are you testifying?**

15 A. I was retained as an independent expert by and am testifying on behalf of Great River
16 Energy, Northern States Power Company, doing business as Xcel Energy, and ITC
17 Midwest LLC (collectively, Applicants), concerning their Joint Certificate of Need
18 Application (Application) to the Minnesota Public Utilities Commission (Commission) for
19 the PowerOn Midwest Project (Project).
20

21 **Q. What is the purpose of your Direct Testimony in this proceeding?**

22 A. To provide information regarding health and safety relating to transmission line noise and
23 electric and magnetic fields.
24

25 II. TESTIMONY OVERVIEW

26

27 **Q. How is your Direct Testimony organized?**

28 A. My Direct Testimony is organized as follows:

- 29 • Section III: Noise
 - 30 • Section IV: Magnetic Fields
- 31

1 **Q. What schedules are attached to your Direct Testimony?**

2 A. The following schedules are attached to my Direct Testimony:

- 3 • **Schedule 1**: Curriculum Vitae

4
5 **Q. Are you sponsoring any sections of the Application?**

6 A. Yes, I am sponsoring Section 8.6 – Electric and Magnetic Fields, as it concerns human
7 health impacts.

8
9 **III. NOISE**

10
11 **Q. What causes noise on transmission lines?**

12 A. As described in Mr. Benjamin Gallay's testimony, corona discharge on transmission lines
13 causes noise under certain conditions, principally atmospheric conditions of foul weather,
14 such as snow, sleet, and freezing rain.

15
16 **Q. Were you provided with modeling data for the corona noise that the Project might
17 create?**

18 A. Yes. The Applicants provided me with modeled sound levels for both the 765 kilovolt (kV)
19 line and 345 kV line facilities. For the 765 kV line, modeling showed a 48.9 A-weighted
20 decibels (dBA) L50 at the edge of the 250-foot right-of-way. For the 345 kV line, the
21 modeled sound level showed 40 dBA for the 345 kV line at the edge of the 345 kV line
22 right-of-way. These levels would decrease as a person moves farther away from the lines.

23
24 **Q. As a neurologist with experience in noise-related health issues, including hearing loss
25 and tinnitus, would you expect transmission line corona noise at the levels modeled at
26 the edge of right-of-way to cause hearing damage or tinnitus?**

27 A. No. This level is substantially below established occupational and public-health thresholds
28 associated with noise-induced hearing loss, tinnitus, or other recognized adverse auditory
29 health effects. For context, regulatory concern for hearing damage does not begin until
30 continuous exposures exceed approximately 85 dBA over an 8-hour period. A 50 dBA

1 sound is therefore far below levels known to cause auditory injury. Fifty dBA is a level of
2 quiet conversation. It is not a risk to human hearing.

3
4 **Q. As a sleep expert, would you expect sleep disruption from transmission line corona**
5 **noise at the levels modeled at the edge of right-of-way?**

6 A. No. I would not expect noise from the transmission line to disrupt sleep. While there is no
7 research study directly addressing this question, we can draw from known principles of
8 acoustics and sleep physiology. I expect corona noise would not disturb sleep for several
9 reasons:

- 10 • Under many operating conditions, corona noise would be minimal, if present at all,
11 and thus likely inaudible.
- 12 • Foul weather, such as wind, rain, sleet, and snow, might result in corona noise.
13 However, at the same time, the ambient (background) noise would also be elevated
14 due to the weather conditions. Elevated ambient noise would often mask corona noise
15 from perception.
- 16 • The noise level relevant for sleep is not the noise level outside the house, it is the
17 noise level inside the bedroom. A typical household reduces external noise by
18 approximately 15 dBA with windows fully open; 20 dBA with partial opening; and
19 25 dBA with full closure.³ So if a maximum corona noise at edge of 250-foot right-
20 of-way would not exceed 50 dBA in foul weather outside, then the bedroom would
21 likely experience at least 15 dBA reduction – and more likely 25 dBA reduction –
22 making the corona noise in the bedroom whisper quiet, likely inaudible, and thus not
23 a risk for sleep disruption.
- 24 • To summarize: corona noise from transmission lines is not constant. When it does
25 occur, it occurs in the context of foul weather, which often masks the noise. And even
26 if maximum predicted noise levels at edge of right-of-way occur in the absence of
27 masking sounds, corona noise would not be expected to disrupt sleep because the
28 levels reaching inside a home would still be low.

³ Locher B et al. Int J Environ Res Public Health. 2018;15(1):149: <https://www.mdpi.com/1660-4601/15/1/149>.

IV. MAGNETIC FIELDS

Q. Do transmission lines produce magnetic fields?


A. Yes. Transmission lines carry alternating electric current. The flow of current through a conductor produces a magnetic field in the surrounding area. The strength of these fields decreases with distance from the line.

Q. Are all magnetic fields the same?

A. No. Magnetic fields span a broad spectrum. Figure 1 is a chart from the National Cancer Institute (NCI) showing the types of magnetic fields across this spectrum. The magnetic fields produced by transmission lines are among the slowest cycling magnetic signals, oscillating at 60 cycles per second. By contrast, visible light oscillates at trillions of cycles per second. Ultraviolet light, x-rays, and gamma rays operate at even higher frequencies.

Figure 1

ELECTROMAGNETIC SPECTRUM



1 **Q. Are magnetic fields from transmission lines the same as ultraviolet light, x-rays, and**
2 **gamma rays?**

3 A. No. Ultraviolet light, x-rays, and gamma rays operate at extraordinarily high frequencies
4 and, at these frequencies, carry enough energy to break chemical bonds, including those in
5 DNA. This process is known as ionization, and fields capable of causing it are classified
6 as ionizing radiation. The 60 hertz (Hz) magnetic fields produced by transmission lines do
7 not carry anywhere near enough energy to cause ionization and are classified as non-
8 ionizing. This is an important distinction, because the health concerns associated with
9 ionizing radiation, such as direct DNA damage, do not apply to the magnetic fields
10 produced by transmission lines.⁴
11

12 **Q. Do magnetic fields from transmission lines cause cancer?**

13 A. No. There is a large body of scientific research, and it does not support a conclusion that
14 magnetic fields from transmission lines cause cancer.
15

16 **Q. Aren't there studies that have found a correlation between transmission lines and**
17 **cancer?**

18 A. Yes. Nearly five decades ago, there was speculation that magnetic fields from power lines
19 might cause childhood leukemia, a form of cancer of the blood. In the subsequent years,
20 there were poorly conducted correlational studies that continued to raise concern. As a
21 result, in 2002, the International Agency for Research on Cancer (IARC) classified
22 extremely low frequency magnetic fields (ELF-MF) as “possibly carcinogenic” (Group
23 2B). This is IARC’s lowest level of positive classification. IARC acknowledged only
24 “limited evidence” and that findings might reasonably be due to chance, bias, or
25 confounding.

⁴ [Electromagnetic Fields and Cancer - https://www.cancer.gov/about-cancer/causes-prevention/risk/radiation/electromagnetic-fields-fact-sheet.](https://www.cancer.gov/about-cancer/causes-prevention/risk/radiation/electromagnetic-fields-fact-sheet)

1 **Q. Has the evidence strengthened or weakened since the 2002 IARC classification?**

2 A. It has weakened. In the decades since, the weight of scientific evidence has moved further
3 away from any association between low-level magnetic field exposure and cancer,
4 including childhood leukemia. No causal mechanism has been identified, and the major
5 health authorities that have reviewed the evidence, including the World Health
6 Organization (WHO), the NCI and the National Institute of Environmental Health Sciences
7 (NIEHS), have not concluded that these fields cause cancer.

8
9 **Q. If the evidence has weakened, why does the IARC still classify ELF magnetic fields as
10 possibly carcinogenic?**

11 A. The IARC has not specified what threshold of new evidence would trigger a re-evaluation
12 of ELF magnetic fields. In 2024, despite decades of accumulated null results, the IARC
13 declined to revisit its 2002 classification. The agency acknowledged that evidence had
14 "weakened," but concluded that re-evaluation was "unwarranted" for 2025–2029.

15
16 As to what level of data would be required to remove ELF magnetic fields from the IARC's
17 Group 2B list, a clue comes from coffee, which carried the same "possibly carcinogenic"
18 Group 2B label from the IARC for 25 years, until review of "more than 1,000 studies"
19 prompted its removal in 2016.⁵

20
21 **Q. Have the National Institutes of Health conducted their own assessment concerning
22 the potential for transmission lines to cause cancer?**

23 A. Yes. The NCI notes that “there is no known mechanism” by which these fields could cause
24 cancer.⁶ In 1999, the NIEHS, concluded that the scientific evidence for a health risk was
25 “weak.”⁷

⁵ Loomis D, Guyton KZ, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, et al.; International Agency for Research on Cancer Monograph Working Group (2016). Carcinogenicity of drinking coffee, mate, and very hot beverages. *Lancet Oncol*, 17(7):877–8. doi:10.1016/S1470-2045(16)30239-X PMID:27318851.

⁶ NCI EMF Fact Sheet (reviewed October 2022, accessed July 2026): <https://www.cancer.gov/about-cancer/causes-prevention/risk/radiation/electromagnetic-fields-fact-sheet>.

⁷ National Institute of Environmental Health Sciences. *NIEHS report on health effects from exposure to power-line frequency electric and magnetic fields*. EMF Research and Public Information Dissemination (EMF RAPID) Program. NIH Publication No. 99-4493. 1999.

1 **Q. Has the WHO provided guidance or opinion concerning the potential for EMF of**
2 **transmission lines to cause health effects?**

3 A. Yes. Since 2007 the WHO maintains the following position: "... EMF limits below the
4 limits recommended in the ICNIRP international guidelines do not appear to have any
5 known consequence on health."⁸
6

7 **Q. What is ICNIRP, and what are their guidelines?**

8 A. "ICNIRP" stands for the International Commission on Non-Ionizing Radiation Protection.
9 ICNIRP establishes guidelines for exposure to non-ionizing sources of magnetic fields,
10 including those from transmission lines. Most of the European Union adopted ICNIRP's
11 1998 guidance for public exposure limits of 830 milli gauss (mG). In 2010, ICNIRP revised
12 their guidelines by increasing acceptable exposure to 2,000 mG.⁹ For context, this Project
13 is expected to produce less than 76 mG at the edge of the 765 kV 250-foot right-of-way.
14 In other words, the reasonable public safety limit according to ICNIRP is many times
15 higher than that which might exist near (or even in) the 250-foot right-of-way.
16

17 **Q. Is there evidence examining the potential for magnetic fields from transmission lines**
18 **to cause interference with implanted electrical devices, including implanted cardiac**
19 **devices?**

20 A. Yes. Tiikkaja et al. published two companion studies in 2013. In the first, volunteers with
21 implanted pacemakers and defibrillators were exposed in a laboratory to magnetic fields
22 far exceeding anything produced by a transmission line. All devices operating in bipolar
23 configuration, showed no interference at any level tested. Bipolar configuration has been
24 the clinical standard for cardiac pacemakers and defibrillators since the mid-1990s. In a
25 companion experiment, Tiikkaja et al. confirmed these findings in the field, showing no
26 interference in volunteers walking directly beneath a 400 kV transmission line.
27

⁸ World Health Organization. Radiation protection norms and standards. World Health Organization
<https://www.who.int/teams/environment-climate-change-and-health/radiation-and-health/protection-norms>. Accessed January 25, 2026.

⁹ International Commission on Non-Ionizing Radiation Protection. Guidelines for limiting exposure to time-varying electric and magnetic fields (1 Hz to 100 kHz). Health Physics. 2010;99(6):818-836.

1 **V. CONCLUSION**

2

3 **Q. Please summarize your opinions discussed in this testimony.**

4 A. With respect to this proposed transmission line and possible health impacts on the public:

5 corona noise will not cause health effects, including hearing problems, tinnitus, or sleep

6 disruption; and magnetic fields will not cause adverse health outcomes, including

7 childhood cancer, or any other form of cancer, or interference from implanted medical

8 devices.

9

10 **Q. Does this conclude your Direct Testimony?**

11 Yes.

Jeffrey M. Ellenbogen, MMSc, MD

Neurology | Sleep Medicine

Baltimore, MD | www.jeffreyellenbogen.com

(Updated January 2026)

CURRENT ACTIVITIES

2024 – present

Medical Director, tele Neurology Clinics (tINIC)

www.tele-neurology.com

Clinical practice featuring patient care in sleep medicine, neurology, and wilderness medicine

2012 – present

Director, The Sound Sleep Project (tISIP)

www.soundsleepproject.com

Scientific consulting services for solutions in sleep and circadian systems

2016 – present

Volunteer firefighter

Baltimore County Fire Department (BCoFD) and Middle River Volunteer Fire Rescue

NATIONAL BOARD CERTIFICATION

1. Neurology (active)
2. Sleep Medicine (active)

OTHER CERTIFICATIONS OR CERTIFICATES

1. DiMM – Diploma in Mountain Medicine
2. FAWM – Fellow in the Academy of Wilderness Medicine
3. FAASM – Fellow of the American Academy of Sleep Medicine
4. ATLS (instructor) – advanced trauma life support
5. AWLS – advanced wilderness life support
6. Avalanche: Level 1 Avalanche Rescue
7. SCUBA: Rescue Diver; Advanced Open Water; Nitrox

CV; Ellenbogen; Page 1 of 7

8. Firefighting: Fire 1; Rescue Ops; Vehicle and Machinery Extrication; Hazardous materials
9. TCCC – tactical combat casualty care
10. Swiftwater Technician – rescue operations involving flood and moving water

EDUCATION & TRAINING

Undergraduate

1994 University of Michigan, Ann Arbor, MI
B.A. (with High Distinction)

Doctoral/graduate

2000 Tufts University School of Medicine, Boston, MA
MD (Doctor of Medicine)

2007 Harvard Medical School, Boston, MA
MMSc (Masters in Medical Science)

Postdoctoral

1 JUL 2000 - 30 JUN 2001
University of Pennsylvania, Philadelphia, PA
Intern, Internal Medicine

1 JUL 2001 - 30 JUN 2004
University of Pennsylvania, Philadelphia, PA
Resident, Neurology

1 JUL 2004 - 30 JUN 2005
University of Pennsylvania, Philadelphia, PA
Fellow, Clinical Electrophysiology

1 JUL 2005 - 30 JUN 2007
Harvard Medical School, Boston, MA
Postdoctoral Fellow in Sleep, Circadian and Respiratory Neurobiology

1 OCT 2019 - 1 JUN 2023
Wilderness Medical Society
Fellow, Academy of Wilderness Medicine

PROFESSIONAL EXPERIENCE

CV; Ellenbogen; Page 2 of 7

1 JUL 2007 - 2012

Massachusetts General Hospital

Chief, Sleep Division

Director, Sleep Laboratory

Physician: Neurologist and Sleep/Circadian Doctor

1 JAN 2009- 30 JUN 2013

Harvard Medical School

Assistant Professor, Neurology and Sleep Medicine

1 JUL 2013 30 JUN 2018:

Johns Hopkins University

Assistant Professor, Neurology

Physician: Neurologist and Sleep-Medicine Doctor, Johns Hopkins Hospital

FEB 2017 – JUN 2020:

Bose Corporation

Subject-matter expert on relationship of sound and sleep

JUL 2019 – AUG 2022

United States Department of Defense

- Associate Professor of Neurology and of Military & Emergency Medicine
Uniformed Services University (USU)
- Vice Chair, Neurology
Uniformed Services University (USU)
- Neurologist and Sleep/Circadian Physician
Walter Reed National Military Medical Center (WRNMMC)
 - Outpatient Clinic, Neurology Department
 - Vestibular Clinic, Otolaryngology Department
 - National Intrepid Center of Excellence (NICoE)

PUBLICATIONS

1. Soutter AD, **Ellenbogen J**, Folkman J. Splenosis is regulated by a circulating factor. *Journal of Pediatric Surgery*. 1994;29:1076-9.
2. Wolfe J, Grier HE, Klar N, Levin SB, **Ellenbogen JM**, Salem-Schatz S, Emanuel EJ, Weeks JC. Symptoms and suffering at the end of life in children with cancer. *New England Journal of Medicine*. 2000;342:326-33.

CV; Ellenbogen; Page 3 of 7

3. Aguirre GK, **Ellenbogen JM**, Pollard J, Stolzenberg ED, Galetta SL. Amyloid angiopathy. *Neurology*. 2002;59:1656.
4. Kolb SJ, Costello F, Lee AG, White M, Wong S, Schwartz ED, Messe SR, **Ellenbogen J**, Kasner SE, Galetta SL. Distinguishing ischemic stroke from the stroke-like lesions of MELAS using apparent diffusion coefficient mapping. *Journal of Neurological Sciences*. 2003;216:11-15.
5. Ances BM, **Ellenbogen JM**, Herman ST, Jacobs D, Liebeskind DS, Chatterjee A, Galetta SL. Balint's syndrome due to Creutzfeldt-Jakob disease. *Neurology*. 2004;63:395.
6. **Ellenbogen JM**. Cognitive benefits of sleep, and their loss due to sleep deprivation. *Neurology*. 2005;64:E25-7.
7. Roy S, **Ellenbogen JM**. Pathologic quiz case: seizures, frontal lobe mass and remote history of periodontal abscess. *Archives of Pathology & Laboratory Medicine*. 2005;129:805-6.
8. **Ellenbogen JM**, Hurford MO, Liebeskind DS, Neimark GB, Weiss D. Ventromedial frontal lobe trauma. *Neurology* 2005;64:757.
9. **Ellenbogen JM**, Hulbert JC, Stickgold R, Dinges DF, Stickgold R, Thompson-Schill SL. Interfering with theories of sleep and memory: Sleep, declarative memory and associative interference. *Current Biology*. 2006;16:1290-1294
10. **Ellenbogen JM**, Payne JD, Stickgold R. The role of sleep in declarative memory consolidation: passive, permissive or active or none? *Current Opinion in Neurobiology*. 2006;16:716-22.
11. **Ellenbogen JM**, Hu PT, Payne JD, Titone D, Walker MP. Human relational memory requires time and sleep. *Proceedings of the National Academy of Science, U S A (PNAS)*. 2007;104:7723-8.
12. **Ellenbogen JM**. The interaction of sleep and memory. In: Chebykin OY, Bedny GB, Karwowski W, eds. *Ergonomics and Psychology: Developments in Theory and Practice*. Taylor and Francis Group; 2008.
13. **Ellenbogen JM**, Hulbert JC, Jiang Y, Stickgold R. The Sleeping Brain's Influence on Verbal Memory: Boosting Resistance to Interference. *PLoS One*. 2009;4:e4117.
14. Dang-Vu TT, McKinney SM, Buxton OM, Solet JM, **Ellenbogen JM**. Spontaneous brain rhythms predict sleep stability in the face of noise. *Current Biology*. 2010;20:R626-R627.
15. **Ellenbogen JM**. Sleep-Specific Atrioventricular Block. *Neurology*. 2010;74:90

16. Dang-Vu TT, Foulkes D, Cartwright RD, **Ellenbogen JM**. Sleep. *Encyclopaedia Britannica*. 2010.
17. McKinney SM, Dang-Vu TT, Buxton OM, Solet JM, **Ellenbogen JM**. Covert waking brain activity reveals instantaneous sleep depth. *PLoS One*. 2011;6:e17351.
18. Babadi B*, McKinney SM*, Tarokh V, **Ellenbogen JM**. Data-Driven Bayesian Algorithm for Sleep Spindle Detection (DiBa). *IEEE Transactions in Biomedical Engineering*. 2012;59(2):483-93.
19. Payne JD, Tucker MA, **Ellenbogen JM**, Wamsley EJ, Walker MP, Schacter DL, Stickgold R. Memory for Semantically Related and Unrelated Declarative Information: The Benefit of Sleep, the Cost of Wake. *PLoS One*. 2012;7:e33079
20. Buxton OM*, **Ellenbogen JM*** (co-first author), Wang W, Carballeira A, O'Connor S, Cooper D, Gordhandas AJ, McKinney SM, Solet JM. Sleep Disruption Due to Hospital Noises: A Prospective Evaluation. *Annals of Internal Medicine*. 2012; 157:170-179.
21. Shaw ND, Butler JP, McKinney SM, Nelson SA, **Ellenbogen JM**, Hall JE. Insights into Puberty: The Relationship Between Sleep Stages and Pulsatile LH Secretion. *The Journal of Clinical Endocrinology and Metabolism*. 2012;97:E2055-62.
22. Fellin T, **Ellenbogen JM**, De Pitta M, Ben-Jacob E, Halassa M. Astrocyte Regulation of Sleep Circuits: Experimental and Modeling Perspectives. *Frontiers in Computational Neuroscience*. 2012;6:65.
23. Eiseman NA, Westover MB, **Ellenbogen JM**, Bianchi MT. The impact of body posture and sleep stages on sleep apnea severity in adults. *Journal of Clinical Sleep Medicine*. 2012;8:655-6.
24. **Ellenbogen JM**, Pace-Schott EF. Drug-induced sleep: Theoretical and practical considerations. *Pflügers Archiv – European Journal of Physiology*. 2012;463(1):177-186.
25. Bianchi MT, Thomas RJ, **Ellenbogen JM**. Hypnotics and Mortality Risk. *The Journal of Clinical Sleep Medicine*. 2012;8(4):351-352
26. **Ellenbogen JM**, Grace S, Heiger-Bernays WJ, et al. Wind Turbine Health Impact Study: Report of Independent Expert Panel. 2012.
27. Bianchi MT, Williams KL, McKinney SM, **Ellenbogen JM**. The subjective-objective mismatch (SOM) in sleep perception among those with insomnia and sleep apnea. *The Journal of Sleep Research*. 2013;22(5):557-568.
28. **Ellenbogen JM**. Noise-induced sleep deprivation: Toward sleeping soundly on noisy nights.

CV; Ellenbogen; Page 5 of 7

In: Bianchi MT. *Sleep Deprivation: Effects on Mind, Body, and Disease*. Springer New York Heidelberg Dordrecht London; 2013.

29. **Ellenbogen JM**. Noise-induced sleep disruption among hospitalized patients: Brain-based approaches toward sleeping soundly on noisy nights. *Noise-Con*. 2013.
30. Marino, M, Li Y, Rueschman MD, Winkelman JW, **Ellenbogen JM**, Solet JM, Dulin H, Berkman LF, Buxton OM. Measuring Sleep: Accuracy, Sensitivity, and Specificity of Wrist Actigraphy Compared to Polysomnography. *Sleep*. 2013;36(11):1147-1155.
31. Pace-Schott EF, Tracy LE, Rubin Z, Mollica AM, **Ellenbogen JM**, Bianchi MT, Milad MR, Pitman RK, Orr SP. Interactions of time of day and sleep with between-session habituation and extinction memory in young adult males. *Experimental Brain Research*. 2014.
32. Geyer MB, **Ellenbogen JM**. Insomnia and Sleep Disorders. In: Kiefer MM, Chong CR, eds. *Pocket Primary Care: A Massachusetts General Hospital Handbook*. Philadelphia: Lippincott Williams & Wilkins; 2014.
33. Prerau MJ, Hartnack KE, Obregon-Henao G, Sampson A, Merlino M, Gannon K, Bianchi MT, **Ellenbogen JM**, Purdon PL. Tracking the Sleep Onset Process: An Empirical Model of Behavioral and Physiological Dynamics. *PLOS Computational Biology*. 2014.
34. Alameddine Y, **Ellenbogen JM**, Bianchi MT. Sleep-Wake Time Perception Varies by Direct or Indirect Query. *Journal of Clinical Sleep Medicine*. 2015.
35. **Ellenbogen JM**. Sleepiness. *Seminars in Neurology*. 2016.
36. Prerau MJ, Bianchi MT, Brown RE, **Ellenbogen JM**, Patrick PL. Sleep neurophysiologic dynamics through the lens of multitaper spectral analysis. *Physiology*. 2017.
37. Akeju O, Hobbs LE, Gao L, Burns SM, Pavone KJ, Plummer GS, Walsh GS, Houle TT, Kim SE, Bianchi MT, **Ellenbogen JM**, Brown EN. Dexmedetomidine promotes biomimetic non-rapid eye movement stage 3 sleep in humans: A pilot study. *Clinical Neurophysiology*. 2017.
38. **Ellenbogen JM, Guay, Christian**. Emergency Sleep Medicine. *Seminars in Neurology*. 2017.
39. Gottlieb DJ, **Ellenbogen JM**, Bianchi MT, Czeisler CA. Sleep deficiency and motor vehicle crash risk in the general population: a prospective cohort study. *BMC Medicine*. 2018.
40. Fogarty AE, Guay, CS, Simoneau G, Colorado BS, Segal GR, Werner JK, **Ellenbogen JM**. Head Motion Predicts Transient Loss of Consciousness in Human Head Trauma a Case-Control Study of Mixed Martial Artists. *American Journal of Physical Medicine and Rehabilitation*. 2019.

41. Goldstein JN, **Ellenbogen JM**. Emergency Neurology. *Seminars in Neurology*. 2019.
42. Schneider L, **Ellenbogen J**. Images: Facial cataplexy with demonstration of persistent eye movements. *Journal of Clinical Sleep Medicine*. 2020.
43. **Ellenbogen JM**. Wind turbine noise and sleep. *SLEEP*. 2022.
44. **Ellenbogen JM**, Guay C. Sound Sleep in the Intensive Care Unit: Source-Path-Receiver Model. *Practical Neurology*. 2023.
45. **Ellenbogen JM**, Kellam CB, Hankard M. Noise-Induced Sleep Disruption from Wind Turbines: Scientific Updates and Acoustical Standards. *SLEEP*. 2024.

LICENSURE and MEMBERSHIPS

Medical licenses:

2004 - 2008	Pennsylvania
2005 - 2014	Massachusetts
2013 - present	Maryland (active)
2023 - 2025	Colorado
2023 - 2025	IMLC (Interstate Medical Licensure Compact)

Boards Memberships:

2005 - present	Neurology (American Board of Psychiatry and Neurology);
2009 - present	Sleep Medicine (American Board of Psychiatry and Neurology)

AWARDS and HONORS

1991	Branstrom Prize for Academic Excellence, University of Michigan
2006 - 2011	Certificate of Distinction in Teaching, Harvard University
2011 - present	Fellow of the American Academy of Sleep Medicine (FAASM)
2011	John E. Dowling Teaching Award in Neurobiology, Harvard University
2012	Wayne A. Hening Sleep Investigator Award, American Academy of Neurology
2017	Firefighter training award, (station 29), Baltimore County Fire Department
2023	Fellow in the Academy of Wilderness Medicine (FAWM)

LEADERSHIP TRAINING

1 JAN 2009 – 31 DEC 2010

Physician Leadership Development Program, MGH/Harvard